Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M6.6Revenue $M1.1Net Margin (%)-1,296.0Altman Z-Score-16.9
Enterprise Value $M-12.4EPS $-1.8Operating Margin %-1,492.2Piotroski F-Score5
P/E(ttm)--Beneish M-Score-3.5Pre-tax Margin (%)-1,296.0Higher ROA y-yY
Price/Book0.410-y EBITDA Growth Rate %1.2Quick Ratio4.7Cash flow > EarningsY
Price/Sales4.25-y EBITDA Growth Rate %-26.9Current Ratio4.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-55.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-70.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M12.2ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with DCTH

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
DCTHGeorge Soros 2011-03-31 Sold Out $98.88 - $183.04
($136.89)
$ 0.55-100%Sold Out0
DCTHGeorge Soros 2010-12-31 Add$115.2 - $180.32
($151.15)
$ 0.55-100%Add 7.14%1,312
DCTHGeorge Soros 2010-09-30 Buy $88.48 - $139.04
($113.58)
$ 0.55-100%New holding1,225
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

DCTH is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


DCTH: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Philips Laura ADirector 2015-07-23Buy162,653$0.50 view
Rueckert William DodgeDirector 2015-07-22Buy20,000$0.484.17 view
APPLING WILLIAM MEVP, R&D and Global Operations 2013-06-25Sell0$04.17 view
APPLING WILLIAM MEVP, R&D and Global Operations 2013-06-25Sell0$04.17 view
LEUNG GABRIELDirector 2012-06-15Buy469$25.12-98.01 view
Koplewicz Harold SDirector 2012-06-01Buy4,167$23.84-97.9 view
Purpura JohnEVP Reg. Affairs/Quality Assur 2012-06-01Buy313$23.84-97.9 view
HOBBS EAMONN PPresident and CEO 2012-06-01Buy438$24.32-97.94 view
Simpson Jennifer K.Exec. VP, Global Marketing 2012-06-01Buy188$23.84-97.9 view
Philips Laura ADirector 2012-06-01Buy4,063$24.16-97.93 view

Quarterly/Annual Reports about DCTH:

News about DCTH:

Articles On GuruFocus.com
comment on DCTH Mar 15 2013 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
cooldecency99 note on DCTH May 01 2010 
cooldecency99 note on DCTH May 01 2010 
Delcath Systems Inc. Reports Operating Results (10-Q) Oct 23 2009 

More From Other Websites
Delcath Receives Orphan Drug Designation From FDA For Melphalan To Treat Cholangiocarcinoma Jul 20 2015
Delcath Receives Orphan Drug Designation From FDA For Melphalan To Treat Cholangiocarcinoma Jul 20 2015
Delcath Announces Pricing Of Public Offering Jul 16 2015
Delcath Announces Pricing Of Public Offering Jul 16 2015
DELCATH SYSTEMS, INC. Files SEC form 8-K, Other Events Jul 07 2015
Delcath Announces Acceptance Of Abstracts For Presentation At The Cardiovascular And Interventional... Jul 04 2015
DELCATH SYSTEMS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 11 2015
DELCATH SYSTEMS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jun 10 2015
Delcath Announces Acceptance Of Abstracts For Presentation At The Cardiovascular And Interventional... Jun 09 2015
Delcath to Webcast Management's Presentation at Annual Meeting of Shareholders on June 10, 2015 Jun 05 2015
Delcath to Webcast Management's Presentation at Annual Meeting of Shareholders on June 10, 2015 Jun 05 2015
Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 May 29 2015
Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 May 29 2015
Delcath's European Key Opinion Leader Forum On CHEMOSAT Therapy Affirms Benefits To Liver Cancer... May 27 2015
Delcath's European Key Opinion Leader Forum On CHEMOSAT Therapy Affirms Benefits To Liver Cancer... May 27 2015
DELCATH SYSTEMS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 26 2015
Delcath Names Dr. Jennifer Simpson President And CEO May 26 2015
Delcath Names Dr. Jennifer Simpson President And CEO May 26 2015
ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open... May 21 2015
ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open... May 21 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK